List of Excipients in Branded Drug TIVORBEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Iroko Pharmaceuticals LLC	TIVORBEX	indomethacin	42211-202	CELLULOSE, MICROCRYSTALLINE
Iroko Pharmaceuticals LLC	TIVORBEX	indomethacin	42211-202	CROSCARMELLOSE SODIUM
Iroko Pharmaceuticals LLC	TIVORBEX	indomethacin	42211-202	FD&C BLUE NO. 1
Iroko Pharmaceuticals LLC	TIVORBEX	indomethacin	42211-202	FD&C BLUE NO. 2
Iroko Pharmaceuticals LLC	TIVORBEX	indomethacin	42211-202	GELATIN

Tivorbex Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Tivorbex is an immediate-release indomethacin capsule marketed in 20 mg and 40 mg strengths for acute painful shoulder and acute gouty arthritis. Its commercial opportunity is limited as a conventional product but remains relevant for generic manufacturers, 505(b)(2) developers, contract manufacturers, and companies pursuing differentiated oral NSAID formulations. The most practical strategies are low-cost ANDA substitution, excipient and capsule-shell optimization, and reformulation into modified-release or gastroprotective products.

What is Tivorbex and how is it formulated?

Tivorbex contains indomethacin, a nonsteroidal anti-inflammatory drug, in immediate-release hard gelatin capsules. The product was approved by the FDA under NDA 205437 through the 505(b)(2) pathway, relying in part on previously established information for indomethacin products.[1]

Product attribute	Tivorbex profile
Active ingredient	Indomethacin
Dosage form	Immediate-release hard gelatin capsule
Strengths	20 mg and 40 mg
Initial FDA approval	2014
Primary indications	Acute painful shoulder and acute gouty arthritis
Regulatory pathway	505(b)(2) NDA
Reference product class	Indomethacin immediate-release products
Biosimilar relevance	None; Tivorbex is a small-molecule drug
Principal commercial issue	Generic substitution and differentiation against established indomethacin products

The lower 20 mg and 40 mg strengths distinguish Tivorbex from commonly marketed 25 mg and 50 mg indomethacin capsules. The lower strengths may support dose titration, although the commercial value depends on prescribing behavior, payer coverage, and generic availability.

What excipients are used in Tivorbex capsules?

The Tivorbex prescribing information identifies a conventional solid oral excipient platform. Public labeling identifies inactive ingredients including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, povidone, sodium lauryl sulfate, and talc. The capsule shell contains gelatin and coloring agents, including titanium dioxide and approved FD&C colors.[1]

Tivorbex excipient functions

Excipient category	Likely function	Commercial relevance
Lactose monohydrate	Diluent and bulking agent	Low cost; creates lactose-intolerance and formulation-exclusion issues for some customers
Microcrystalline cellulose	Diluent and compression or fill aid	Supports flow and content uniformity
Croscarmellose sodium	Superdisintegrant	Helps achieve rapid capsule-fill dispersion
Povidone	Binder and processing aid	Supports granulation and powder cohesion
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder handling and fill-weight consistency
Magnesium stearate	Lubricant	Reduces tooling and manufacturing friction; excess can slow wetting
Sodium lauryl sulfate	Wetting agent	May improve indomethacin dispersion, but can create tolerability and regulatory scrutiny
Talc	Processing aid and anti-adherent	Supports manufacture; requires tight control of quality and contamination risk
Gelatin	Capsule-shell material	Standard, but unsuitable for some vegetarian, religious, or animal-origin restricted markets
Titanium dioxide and colorants	Capsule identification	Supports strength differentiation and brand recognition

The excipient system is not a strong standalone commercial barrier. Most listed materials are common pharmaceutical excipients with broad supplier availability and established FDA Inactive Ingredient Database precedent.[2] The more defensible technical value lies in the quantitative composition, particle-size distribution, manufacturing process, dissolution profile, and capsule-fill uniformity rather than in the identity of individual excipients.

What excipient strategy is most appropriate for generic Tivorbex?

A conventional ANDA strategy should preserve the product’s immediate-release performance while minimizing avoidable formulation complexity. The target should be pharmaceutical equivalence, bioequivalence, and reliable content uniformity at both strengths.

Recommended generic formulation strategy

A generic manufacturer would normally evaluate:

1. A lactose-based formulation using microcrystalline cellulose and croscarmellose sodium.
2. A lactose-free formulation using mannitol, microcrystalline cellulose, or dibasic calcium phosphate.
3. A low-surfactant or surfactant-free formulation if dissolution can be maintained.
4. A gelatin capsule and a hypromellose capsule for market segmentation.
5. Separate color systems for 20 mg and 40 mg to reduce dispensing errors.

Indomethacin is poorly soluble in water and has dose-related gastrointestinal risk. Formulation work therefore should focus on rapid wetting, reproducible dispersion, and dissolution across physiological pH conditions. Sodium lauryl sulfate may assist wetting, but its concentration should be optimized against capsule compatibility, taste exposure after accidental opening, and gastrointestinal tolerability.

The main technical risks

Development risk	Impact on Tivorbex opportunity
Slow or variable dissolution	Can jeopardize bioequivalence and create food-effect differences
Excessive lubricant concentration	May reduce wetting and delay drug release
Indomethacin particle-size variability	Can alter dissolution and fill uniformity
Capsule-shell moisture migration	May affect stability and mechanical performance
Lactose-related compatibility issues	Can exclude patients or institutional buyers seeking lactose-free products
Surfactant sensitivity	Can complicate tolerability, stability, and formulation justification
Low-dose content-uniformity challenges	More significant for the 20 mg strength
Colorant or gelatin restrictions	May limit international or specialty-market adoption

A generic company should avoid unnecessary excipient departures unless the change creates a measurable commercial or regulatory advantage. For an immediate-release product, a simple, well-characterized formulation is usually more valuable than a complex excipient system that creates additional comparative dissolution and stability work.

What formulation patents protect Tivorbex?

The commercial protection for Tivorbex should be separated into four categories:

• Drug-substance patents covering indomethacin itself.
• Formulation patents covering the excipient composition or release characteristics.
• Method-of-use patents covering specific indications or dosing regimens.
• Manufacturing patents covering granulation, particle engineering, capsule filling, or stability improvements.

Indomethacin is an old small-molecule active ingredient, so the active-ingredient composition is not the principal barrier to entry. Any meaningful remaining exclusivity would more likely depend on formulation, dosing, or method-of-use claims.

A Tivorbex competitor should review:

• The FDA Orange Book patent listing for NDA 205437.[3]
• FDA patent-certification and exclusivity records.
• U.S. Patent and Trademark Office prosecution histories.
• Patent assignments and continuation applications.
• ANDA litigation records under the Hatch-Waxman framework.
• International filings covering the 20 mg and 40 mg capsule compositions.

A formulation patent directed only to an excipient identity may be vulnerable if the same performance can be achieved with routine substitutions. Claims tied to a defined dissolution profile, pharmacokinetic exposure, particle-size range, or manufacturing sequence may present a stronger barrier.

When does Tivorbex lose exclusivity?

Tivorbex does not have biologic exclusivity, and biosimilar competition does not apply. Generic entry depends on the status of FDA regulatory exclusivity, Orange Book-listed patents, settlement agreements, and any enforceable formulation or method-of-use claims.

Exclusivity and entry framework

Protection	Relevance to Tivorbex
New chemical entity exclusivity	Unlikely to be relevant because indomethacin predates Tivorbex
3-year clinical investigation exclusivity	Potentially relevant to the 505(b)(2) approval, depending on the approved labeling and exclusivity record
Orphan-drug exclusivity	Not generally associated with Tivorbex’s listed indications
Pediatric exclusivity	Requires a specific FDA grant and should be verified in current FDA records
Listed patents	May delay ANDA approval or trigger Paragraph IV litigation
Method-of-use claims	May be carved out through a section viii statement if legally and regulatorily appropriate
Formulation claims	Could require a Paragraph IV challenge or a non-infringing formulation
Regulatory exclusivity expiration	Must be confirmed through Drugs@FDA and Orange Book data

The initial approval date alone does not establish the end of all potential market protection. FDA exclusivity and patent expiry are separate calculations. An ANDA applicant should model entry under three scenarios: approval after patent expiry, approval after litigation settlement, and launch at risk following a successful Paragraph IV position.

What Paragraph IV challenges could affect Tivorbex?

An ANDA applicant may certify under Paragraph IV that a listed patent is invalid, unenforceable, or not infringed. The first applicant to submit a substantially complete Paragraph IV challenge can, where statutory conditions are met, qualify for 180-day generic exclusivity.[4]

For Tivorbex, the likely challenge targets would be:

• A formulation patent covering the immediate-release capsule composition.
• A patent covering a defined low-dose regimen.
• A patent claiming a specific dissolution or bioavailability profile.
• A process patent tied to powder preparation or capsule filling.

A section viii statement may be more efficient for method-of-use patents that are not required for the proposed generic label. That approach can avoid directly challenging a method patent, although it requires careful labeling analysis.

No confirmed current Paragraph IV litigant, settlement agreement, or commercial launch date should be treated as established without checking the active FDA Orange Book, court dockets, and ANDA litigation records. The relevant legal risk is claim-specific, not determined by the brand name alone.

What commercial opportunities exist for Tivorbex excipients?

1. Low-cost ANDA substitution

The largest opportunity is a conventional generic capsule using widely available excipients. Manufacturers can compete through:

• Lower-cost lactose or lactose-free platforms.
• Dual sourcing of microcrystalline cellulose, croscarmellose sodium, and capsule shells.
• Improved manufacturing yields.
• Strength-specific capsule color coding.
• Simplified packaging and institutional supply contracts.

Because indomethacin is an established generic molecule, price competition is likely to dominate unless a supplier offers reliable availability or a differentiated formulation.

2. Lactose-free and animal-origin-free capsules

A lactose-free version could target patients with lactose sensitivity and institutional buyers with excipient restrictions. Hypromellose capsules could address vegetarian, halal, kosher, and animal-origin concerns. These products would not automatically receive premium pricing, but they may support specialty-channel positioning.

The commercial value depends on whether the alternative excipient system maintains bioequivalence and rapid dissolution without creating a new clinical or labeling burden.

3. Modified-release indomethacin

A modified-release product could seek longer dosing intervals or lower peak exposure. The technical problem is substantial: changing release kinetics can alter efficacy, gastrointestinal exposure, and safety. A modified-release product would likely require a 505(b)(2) strategy rather than a conventional ANDA if it is not therapeutically equivalent to an immediate-release reference product.[5]

Potential technologies include:

• Hydrophilic matrix systems.
• Multiparticulate pellets.
• Enteric-coated particles.
• Amorphous solid dispersions.
• Lipid-based or self-emulsifying systems.

The strongest commercial case would require clinical evidence showing a meaningful dosing or tolerability advantage. An excipient change alone is unlikely to support a durable premium.

4. Gastroprotective combination products

A combination of indomethacin with a proton-pump inhibitor or another gastroprotective agent could address NSAID-related gastrointestinal risk. This would be a new product strategy, not a simple generic Tivorbex substitute. It would require careful regulatory positioning, drug-interaction analysis, and clinical support.

A combination product could generate stronger intellectual property if the claims cover a defined ratio, dosing schedule, patient population, or pharmacokinetic relationship. The development cost and safety burden would also be materially higher.

5. Hospital and acute-care formulations

Acute gout and painful shoulder treatment create an opportunity for products optimized for rapid administration. Possible platforms include:

• Smaller capsules for swallowing ease.
• Sprinkle-compatible multiparticulates.
• Orally disintegrating formulations.
• Liquid-filled capsules.
• Unit-dose blister packaging.

These products may require new clinical or comparative-performance work. An orally disintegrating formulation also raises taste-masking and local irritation issues because indomethacin is pharmacologically active at low exposure levels.

How does Tivorbex compare with other indomethacin products?

Factor	Tivorbex	Conventional indomethacin generic	Modified-release indomethacin
Strengths	20 mg and 40 mg	Commonly 25 mg and 50 mg	Product-specific
Release	Immediate	Immediate	Extended or delayed
Regulatory route	505(b)(2) originator	Usually ANDA	Often 505(b)(2)
Excipient differentiation	Moderate	Usually limited	High
Bioequivalence complexity	Standard but dissolution-sensitive	Standard	Higher
Patent opportunity	Formulation and use claims	Limited unless new formulation	Potentially stronger
Price pressure	High	Very high	Potentially lower
Commercial differentiation	Dose flexibility and branding	Low-cost supply	Dosing convenience or tolerability

Tivorbex’s lower strengths are its clearest product-level differentiator. That advantage is weaker if generic manufacturers can market therapeutically equivalent doses through tablet or capsule combinations.

What is the FDA regulatory status of Tivorbex?

Tivorbex was approved as an indomethacin capsule under NDA 205437. FDA labeling identifies the product as an immediate-release oral capsule for specified acute inflammatory conditions.[1] The product is subject to the standard small-molecule drug framework: NDA approval, Orange Book listing, ANDA substitution rules, patent certifications, and potential 505(b)(2) competition.

FDA’s Inactive Ingredient Database is important for excipient strategy because it provides precedent for route, dosage form, and maximum potency levels. It does not establish that a proposed formulation is bioequivalent or clinically interchangeable.[2]

How strong is the Tivorbex patent estate?

The patent estate is likely weaker around the indomethacin molecule and stronger only to the extent that claims cover a specific Tivorbex formulation, dose, manufacturing process, or clinical use. The strongest commercial claims would generally have:

• Clear structural or compositional boundaries.
• A measurable dissolution or pharmacokinetic limitation.
• Evidence that the claimed excipient combination produces an unexpected result.
• Support across both 20 mg and 40 mg strengths.
• Enforceability during the expected generic-entry period.

A generic applicant should prioritize a non-infringing formulation design around excipient ratios, capsule composition, particle-size distribution, or manufacturing sequence before relying exclusively on invalidity arguments.

Key Takeaways

• Tivorbex is an immediate-release indomethacin capsule in 20 mg and 40 mg strengths.
• Its excipient platform is conventional and generally substitutable.
• Lactose-free and hypromellose-capsule versions offer the most accessible differentiation.
• Rapid dissolution, low-dose content uniformity, and indomethacin particle-size control are the principal technical issues.
• The largest commercial opportunity is a low-cost ANDA supported by reliable supply and a simple formulation.
• Modified-release, gastroprotective, and orally disintegrating products could support higher value but would likely require a 505(b)(2) strategy.
• Patent risk is more likely to arise from formulation, manufacturing, or method-of-use claims than from indomethacin itself.
• Biosimilar competition is irrelevant because Tivorbex is a small-molecule drug.
• Orange Book listings, FDA exclusivity records, USPTO prosecution histories, and Hatch-Waxman litigation records should control any launch-timing analysis.

FAQs

Can a generic Tivorbex product use different excipients?

Yes. An ANDA applicant can generally use different inactive ingredients if the product remains pharmaceutically equivalent, meets applicable safety requirements, and demonstrates bioequivalence. Differences that affect dissolution, absorption, stability, or labeling may increase regulatory complexity.

Is a lactose-free Tivorbex formulation commercially attractive?

It can support specialty positioning and institutional procurement, particularly where lactose or animal-origin restrictions apply. Its premium potential is limited unless the product also offers improved tolerability, supply reliability, or another clinically relevant advantage.

Would an enteric-coated indomethacin product avoid Tivorbex patents?

Not necessarily. Enteric coating may avoid a claim limited to an immediate-release capsule, but it could infringe broader formulation or method claims. It would also create new dissolution, food-effect, and bioequivalence requirements.

Can a company launch generic indomethacin before all Tivorbex patents expire?

Potentially. A company may rely on a Paragraph IV certification, a section viii carve-out for method-of-use patents, a non-infringing formulation, or a settlement agreement. The legally available route depends on the specific Orange Book-listed claims.

Does Tivorbex have biosimilar or interchangeable-product risk?

No. Biosimilar and interchangeable-product pathways apply to biological products. Tivorbex is a chemically synthesized small-molecule indomethacin product and is subject to generic-drug pathways instead.

References

1. U.S. Food and Drug Administration. (2014). Tivorbex (indomethacin) capsules prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Refuse-to-receive standards and Paragraph IV certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

5. U.S. Food and Drug Administration. (n.d.). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-resources/505b2-application-program-part-ii-guidance-industry